Navigation Links
BSGI/MBI Shows Greater Sensitivity and Comparable Specificity When Compared to Ultrasound and Mammography
Date:11/29/2011

NEWPORT NEWS, Va., Nov. 29, 2011 /PRNewswire/ -- When compared to mammography and ultrasound, Breast-Specific Gamma Imaging (BSGI), also known as Molecular Breast Imaging (MBI), has greater sensitivity and comparable specificity according to a new study that will be presented at the 2011 Radiological Society of North America (RSNA) annual meeting to be held in Chicago, Nov. 27 through Dec. 2, 2011. BSGI/MBI also proved to be a valuable adjunctive procedure when mammography and ultrasound fail to provide a confident breast cancer diagnosis.

"This study helped show the power of BSGI, especially in patients with indeterminate results on mammography or ultrasound," said Jean Weigert, M.D., first author on the study. "Many suspicious areas can show up on an ultrasound. BSGI helps us focus on the areas of true positive and determine where to biopsy."

Four institutions participated in the study to compare BSGI/MBI to mammography (MMG) and ultrasound (US) in patients who required diagnostic imaging due to clinical or radiographic findings.  The researchers on the study include radiologists Jean M. Weigert of Bradley Memorial Hospital in New Britain, Conn.; Margaret L. Bertrand of the Solis Bertrand Breast Center in Greensboro, N.C.;  Leora Lanzkowsky of Nevada Imaging in Las Vegas, Nev.; Lillian H. Stern of Methodist Hospital in Philadelphia.

For this study BSGI/MBI was conducted with a high-resolution gamma camera, the Dilon 6800®. It was concluded that BSGI/MBI has greater sensitivity and comparable specificity compared to ultrasound and mammography, and is a valuable adjunctive procedure when these anatomical imaging modalities fail to provide a confident diagnosis. BSGI/MBI is also a useful diagnostic modality to augment mammography in the management of patients with difficult to diagnose breast tissue, and in cases where unresolved clinical concern remains after a mammogram.

"The results of the study increase my confidence in BSGI as an imaging tool for breast cancer detection, pre-treatment disease extent workup, and post-treatment monitoring," said Dr. Leora Lanzkowsky. "It provides an alternative for patients unable to undergo MRI when needed. It raises the confidence level when a biopsy is considered, therefore helping to avoid unnecessary morbidity."

About BSGI/MBI

As a follow-up to mammography, BSGI/MBI utilizes the Dilon 6800® Gamma Camera to help physicians more clearly differentiate benign from malignant tissue. To perform BSGI/MBI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal healthy cells and generally appear as dark spots on the BSGI/MBI image.

About Dilon Diagnostics

Dilon Diagnostics, a brand of Dilon Technologies Inc., is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800®, is a high-resolution, small field-of view gamma camera, optimized to perform BSGI/MBI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI/MBI to their patients, such as Cornell University Medical Center, New York and The George Washington University Medical Center, Washington, D.C. For more information on Dilon Technologies please visit www.dilon.com.

Media contact: Kristine Brown
P: 847-528-2145
E: kbrown@imschicago.com


'/>"/>
SOURCE Dilon Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Shows BSGI/MBI Contributes Significantly to Patient Management with Its Ability to Detect Breast Cancer in Difficult to Diagnose Patients
2. New Analysis Shows Downward Trend in Imaging Utilization
3. Medco Research Institute Study Shows Some Patients Discontinue New Anticoagulant Drug Early, Which May Increase Stroke Risk
4. National Campaign Shows Veterans Why "Its Worth the Fight" Against Advanced Prostate Cancer
5. Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease
6. Study Shows Efficacy of C1-Esterase Inhibitor Concentrate in Treating Acute Attacks of Hereditary Angioedema in Children and Adolescents
7. Life Sciences Venture Capital Investing Falls 18% in Q3 2011 from Prior Quarter but Still Shows an Increase of 22% from Q3 2010, According to the MoneyTree Report
8. Study Shows New Medication Effectively Treats Underlying Cause of Cystic Fibrosis
9. Merz research Shows Long-term Benefits for Patients With Dystonia
10. EU Study Shows Once-Daily Lisdexamfetamine Dimesylate (LDX) Effective for Symptom Control in Children and Adolescents with ADHD
11. Global Sources opens six trade shows with worlds top buyers registered to attend including Adidas, AEON, American Greetings, Brookstone, Casino, Coles Group, Mothercare, Next, Sears and Woolworths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... COTTAGE, New York , February 20, 2017 /PRNewswire/ ... a regularized absorption of calcium and phosphorous minerals in ... role of vitamin D ingredients in maintaining a healthy ... or medicines containing vitamin D ingredients is growing in ... the advantage of consuming vitamin D ingredients for treatment ...
(Date:2/19/2017)... Fla. , Feb. 19, 2017  nThrive™, ... revenue cycle portfolio and thought leadership at the ... receiving a category leader award from KLAS. ... panel discussion focused on how market trends shape ... -  particularly a sophisticated, comprehensive Patient Access solution. ...
(Date:2/18/2017)... 17, 2017   Parker Waichman LLP, ... rights of victims injured by medical devices, comments ... call for better reporting. Congress required hospitals to ... concerns involving power morcellators and duodenoscopes prompted the ... how hospitals report injuries and deaths related to ...
Breaking Medicine Technology:
(Date:2/18/2017)... , ... February 17, 2017 ... ... for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March 1, 2017 ... manufacturers looking to reduce their regulatory burden? Pay dividends in enhanced and ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, ... on the Pet Life Radio network. The episode, which was posted this week, ... including: what factors led to Park Cities Pet Sitter’s being awarded the 2017 National ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... pace. Enovate Medical has introduced an innovative workstation designed to reduce nursing fatigue ... the Encore Mobile EHR Workstation offers a lightweight, highly mobile, multi-functional alternative to ...
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... ... ... to Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. ... , What are the critical reimbursement questions manufacturers should be asking ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
Breaking Medicine News(10 mins):